SAN FRANCISCO (AFX) - Trimeris Inc and Roche said late Thursday that data supports the continued development of two next-generation HIV fusion inhibitor peptide candidates.
Fusion inhibitors work by blocking viral entry into human immune cells.
The peptides were discovered by Trimeris scientists and selected by the both companies for progression into full pre-clinical development last month.
Roche and Trimeris currently market Fuzeon, the only fusion inhibitor currently available for the treatment of HIV. newsdesk@afxnews.com jfr
COPYRIGHT
Copyright AFX News Limited 2005. All rights reserved. The copying, republication or redistribution of AFX News Content,inculding by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
For more information and to contact AFX: www.afxnews.com and www.afxpress.com
Fusion inhibitors work by blocking viral entry into human immune cells.
The peptides were discovered by Trimeris scientists and selected by the both companies for progression into full pre-clinical development last month.
Roche and Trimeris currently market Fuzeon, the only fusion inhibitor currently available for the treatment of HIV. newsdesk@afxnews.com jfr
COPYRIGHT
Copyright AFX News Limited 2005. All rights reserved. The copying, republication or redistribution of AFX News Content,inculding by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
For more information and to contact AFX: www.afxnews.com and www.afxpress.com
© 2006 AFX News
